Opioid use disorder (OUD), which contributes to the ongoing overdose crisis claiming over 21 lives across Canada a day, is even more severe within correctional settings. In North America, OUD is a ...
Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...
RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical ...
Hosted on MSN
Injectable, extended-release buprenorphine feasible for opioid use disorder during pregnancy
FRIDAY, March 20, 2026 (HealthDay News) -- Injectable, extended-release buprenorphine is safe and effective in pregnant women with opioid use disorder (OUD), according to a study published online ...
For adults with high-risk opioid use disorder (OUD), both 100-mg or 300-mg monthly maintenance injections of extended-release buprenorphine improved opioid abstinence, but the higher dose seemed to ...
More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.
In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.
LUND, Sweden, June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 ...
About The Study: In this multicenter randomized clinical trial, rapid induction had higher retention than standard induction overall and in patients who tested positive for fentanyl through ...
Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...
CLEVELAND, Ohio — A longer-acting medication may be more effective at helping pregnant women with opioid use disorder avoid illegal drugs, suggests new research from the University of Cincinnati.
Leads to superior rates of illicit opioid abstinence and improved outcomes compared with sublingual buprenorphine. HealthDay News — Injectable, extended-release buprenorphine is safe and effective in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results